Zhengye Biotechnology Holding (ZYBT) Cash & Equivalents (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Cash & Equivalents for 3 consecutive years, with $7.1 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents rose 173.98% year-over-year to $7.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.1 million (up 173.98% YoY) and the FY2025 annual result came in at $7.2 million, up 170.46% from the prior year.
• Cash & Equivalents advanced to $7.1 million in Q4 2025 per ZYBT's latest filing, from $6.4 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ZYBT reached as high as $7.1 million in Q4 2025 and fell as low as $2.6 million in Q4 2024.
• A 3-year average of $5.0 million and a median of $5.1 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 31.4% — and 2025, when it surged 173.98%.
• Year by year, Cash & Equivalents stood at $3.8 million in 2023, then sank by 31.4% to $2.6 million in 2024, then jumped by 173.98% to $7.1 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.1 million, $6.4 million, and $2.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.